187 related articles for article (PubMed ID: 32063014)
1. The Risk of Nephrogenic Systemic Fibrosis in Group II and III Gadolinium-Based Contrast Agents.
Costa AF
Can Assoc Radiol J; 2020 Nov; 71(4):536. PubMed ID: 32063014
[No Abstract] [Full Text] [Related]
2. [Nephrogenic systemic fibrosis and gadolinium contrast agents].
Aguilera C; Agustà A
Med Clin (Barc); 2011 May; 136(14):643-5. PubMed ID: 21397280
[No Abstract] [Full Text] [Related]
3. How to avoid nephrogenic systemic fibrosis: current guidelines in Europe and the United States.
Thomsen HS
Radiol Clin North Am; 2009 Sep; 47(5):871-5, vii. PubMed ID: 19744601
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic Hemodialysis for Protection Against Gadolinium-Induced Nephrogenic Systemic Fibrosis: A Doll's House.
Yee J
Adv Chronic Kidney Dis; 2017 May; 24(3):133-135. PubMed ID: 28501073
[No Abstract] [Full Text] [Related]
5. Gadolinium and nephrogenic systemic fibrosis: have the alarm bells been silenced?
Tamburrini O; Balducci A
Radiol Med; 2012 Feb; 117(1):1-5. PubMed ID: 22020430
[TBL] [Abstract][Full Text] [Related]
6. Nephrogenic systemic fibrosis: the need for accurate case reporting.
Spinazzi A; Kirchin MA; Pirovano G
J Magn Reson Imaging; 2009 May; 29(5):1240; author reply 1241. PubMed ID: 19388104
[No Abstract] [Full Text] [Related]
7. Nephrogenic systemic fibrosis: possible mechanisms and imaging management strategies.
Dawson P
J Magn Reson Imaging; 2008 Oct; 28(4):797-804. PubMed ID: 18821621
[No Abstract] [Full Text] [Related]
8. Nephrogenic systemic fibrosis.
Weinreb JC; Kuo PH
Magn Reson Imaging Clin N Am; 2009 Feb; 17(1):159-67. PubMed ID: 19364606
[TBL] [Abstract][Full Text] [Related]
9. Nephrogenic systemic fibrosis and gadolinium: a cautionary tale in the molecular imaging era.
Wang SC
J Med Imaging Radiat Oncol; 2008 Aug; 52(4):305-6. PubMed ID: 18811752
[No Abstract] [Full Text] [Related]
10. [Causal relationship between the use of gadolinium based contrast media and nephrogenic systemic fibrosis].
Varela CU; Prieto-Rayo JC
Rev Med Chil; 2014 Dec; 142(12):1565-74. PubMed ID: 25693439
[TBL] [Abstract][Full Text] [Related]
11. Safety of magnetic resonance contrast media: a review with special focus on nephrogenic systemic fibrosis.
Haneder S; Kucharczyk W; Schoenberg SO; Michaely HJ
Top Magn Reson Imaging; 2015 Feb; 24(1):57-65. PubMed ID: 25654421
[No Abstract] [Full Text] [Related]
12. NSF prevention in clinical practice: summary of recommendations and guidelines in the United States, Canada, and Europe.
Leiner T; Kucharczyk W
J Magn Reson Imaging; 2009 Dec; 30(6):1357-63. PubMed ID: 19937935
[TBL] [Abstract][Full Text] [Related]
13. Experimental studies investigating the pathophysiology of nephrogenic systemic fibrosis; what did we learn so far?
Morcos SK
Eur Radiol; 2011 Mar; 21(3):496-500. PubMed ID: 20848109
[No Abstract] [Full Text] [Related]
14. Nephrogenic systemic fibrosis and class labeling of gadolinium-based contrast agents by the Food and Drug Administration.
Yang L; Krefting I; Gorovets A; Marzella L; Kaiser J; Boucher R; Rieves D
Radiology; 2012 Oct; 265(1):248-53. PubMed ID: 22923714
[TBL] [Abstract][Full Text] [Related]
15. Current status of nephrogenic systemic fibrosis.
Daftari Besheli L; Aran S; Shaqdan K; Kay J; Abujudeh H
Clin Radiol; 2014 Jul; 69(7):661-8. PubMed ID: 24582176
[TBL] [Abstract][Full Text] [Related]
16. Updates to the ACR Manual on Contrast Media.
Kodzwa R
Radiol Technol; 2017 Nov; 89(2):186-189. PubMed ID: 29298922
[No Abstract] [Full Text] [Related]
17. Gadolinium-associated nephrogenic systemic fibrosis.
Schlaudecker JD; Bernheisel CR
Am Fam Physician; 2009 Oct; 80(7):711-4. PubMed ID: 19817341
[TBL] [Abstract][Full Text] [Related]
18. Application of extracellular gadolinium-based MRI contrast agents and the risk of nephrogenic systemic fibrosis.
Heverhagen JT; Krombach GA; Gizewski E
Rofo; 2014 Jul; 186(7):661-9. PubMed ID: 24477507
[TBL] [Abstract][Full Text] [Related]
19. Recent topics related to nephrogenic systemic fibrosis associated with gadolinium-based contrast agents.
Kitajima K; Maeda T; Watanabe S; Ueno Y; Sugimura K
Int J Urol; 2012 Sep; 19(9):806-11. PubMed ID: 22571387
[TBL] [Abstract][Full Text] [Related]
20. Canadian Association of Radiologists national advisory on gadolinium administration and nephrogenic systemic fibrosis.
Padilla-Thornton A; Zand KR; Barrett B; Stein L; Andrew G; Forster BB
Can Assoc Radiol J; 2008 Dec; 59(5):237-40. PubMed ID: 19385151
[No Abstract] [Full Text] [Related]
[Next] [New Search]
